格隆汇1月27日丨广信材料(300537.SZ)公布，预计2025年归属于上市公司股东的净利润1,350万元–2,000 万元，同比扭亏为盈，扣除非经常性损益后的净利润400万元–600万元，同比扭亏为盈。2025年度，公 司聚焦各类功能涂层材料、光刻胶及配套材料等主营业务领域拓展，在稳固PCB光刻胶、消费电子涂料 等电子材料稳健增长的基础上，加速海洋工程涂料、高性能特种功能涂料等领域相关功能材料的产业布 局，并完成龙南基地的大部分产能的建设和试生产投产工作，进一步整合公司资产、优化产品结构，通 过集中生产提高经营效率。经初步测算，报告期内公司预计实现营业收入约4.8亿元，归属于上市公司 股东的净利润及扣除非经常性损益后的净利润均实现了扭亏为盈。 ...

何氏眼科表示，报告期内，公司业绩实现扭亏为盈，得益于业务结构优化、成本费用有效控制及低效资 产出清，公司盈利能力显著增强。 北京商报讯(记者丁宁)1月27日晚间，何氏眼科（301103）发布2025年业绩预告显示，公司预计2025年 实现归属净利润2400万元至3600万元，将实现扭亏为盈。 ...

Group 1 - The core viewpoint of the article is that Aoyuan Ceiling expects to achieve a net profit of 10 million to 14 million yuan for the year 2025, marking a turnaround from a loss in the previous year [1] - The basic earnings per share are projected to be between 0.08 yuan and 0.12 yuan, compared to a loss of 0.86 yuan per share in the same period last year [1] - The significant change in performance is attributed to the company's focus on its main business, improved management practices, and effective cost control measures, which have enhanced profitability [1] Group 2 - In 2024, the company incurred substantial asset impairment and credit impairment provisions, which led to losses [1] - The company has successfully turned around its performance by emphasizing cost reduction and efficiency improvements [1]

（文章来源：北京商报） 北京商报讯1月27日晚间，智光电气（002169）发布2025年度业绩预告显示，公司预计全年实现归属净 利润1.1亿—1.6亿元，同比扭亏为盈，上年同期为亏损3.26亿元。 智光电气表示，本报告期公司的储能业务快速发展，订单量和收入大幅增长，且已投运的独立储能电站 效益较好，本报告期毛利额增加较多；受公司间接投资的粤芯半导体估值变动影响，本报告期公司公允 价值变动损益增长较多。 ...

Core Viewpoint - The company, Boliwei (688345), forecasts a significant turnaround in its financial performance for the year 2025, expecting a net profit of approximately 59 million yuan, compared to a loss of about 96.6 million yuan in 2024, driven by increased sales in electric motorcycles and battery-swapping services [1] Financial Performance - The projected net profit attributable to the parent company for 2025 is around 59 million yuan, with a net profit of approximately 41 million yuan after deducting non-recurring gains and losses, indicating a return to profitability [1] - In the previous year (2024), the company reported a net loss of 96.6 million yuan, highlighting a significant improvement in financial performance [1] Business Drivers - The primary reasons for the expected substantial growth and return to profitability include increased sales volume in electric motorcycles and battery-swapping services, as well as a recovery in the European electric bicycle market [1] - The release of production capacity has led to economies of scale, alongside ongoing improvements in cost control and operational efficiency, contributing to the notable increase in revenue and net profit [1] Additional Notes - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by a registered accountant; the final and accurate financial data will be disclosed in the officially audited annual report for 2025 [1]

重要内容提示： 广东博力威科技股份有限公司（以下简称"公司"）预计2025年实现归属于母公司所有者的净利润约 5,900.00万元，实现归属于母公司所有者扣除非经常性损益后的净利润约4,100.00万元，实现扭亏为盈。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 1、经财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利润与上年同期相比，将实现 扭亏为盈，实现归属于母公司所有者的净利润约5,900.00万元。 2、预计2025年度实现归属于母公司所有者扣除非经常性损益后的净利润约4,100.00万元。 公司2024年利润总额为-13,106.29万元；实现归属于上市公司股东的净利润-9,660.78万元；实现归属于 上市公司股东扣除非经常性损益的净利润为-8,442.19万元；实现每股收益为-0.97元。 三、本期业绩变化的主要原因 本期业绩变化主要系公司电摩、两轮车换电业务放量，推动大圆柱电芯实现满 ...

人民财讯1月26日电，奥瑞德（600666）1月26日公告，预计2025年度实现归属于母公司所有者的净利润 为1.2亿元到1.6亿元，与上年同期相比，将实现扭亏为盈。 ...

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 135 million to 155 million yuan for the year 2025, marking a turnaround from losses in the previous year [1] Financial Performance - The projected net profit for 2025 represents a significant improvement compared to the previous year, indicating a recovery in financial performance [1] - The expected net profit after deducting non-recurring gains and losses is estimated to be between 120 million and 140 million yuan [1] Product and Market Dynamics - The sales price of the company's main product, Acetochlor, has significantly increased compared to the same period last year, contributing to an overall improvement in product gross margins [1] - The successful launch and sales of the newly developed product series, Pyrazole, have further driven the growth of gross margins for domestic formulation products [1] Operational Efficiency - The company is continuously advancing operational reforms and implementing a gross profit distribution plan, which enhances cost and expense management [1] - Overall operational efficiency is improving as a result of these initiatives [1]

Group 1 - The core point of the article is that Yiling Pharmaceutical (002603.SZ) has forecasted a significant turnaround in its financial performance for 2025, expecting a net profit of between 1.2 billion to 1.3 billion yuan, compared to a loss of approximately 725 million yuan in 2024, indicating a successful recovery and substantial profit growth [1] - Yiling Pharmaceutical's wholly-owned subsidiary, Yiling Wanzhou International Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its first independently developed chemical drug, Manshuan (Phenylacetone Injection), marking a significant milestone for the company [1][3] - The approval of Phenylacetone Injection provides a new treatment option for postoperative pain management, particularly in abdominal and thoracoscopic surgeries, aligning with the guidelines from the Chinese Medical Association [3][4] Group 2 - According to the National Bureau of Statistics, there were 312 million inpatient admissions and 104 million surgical procedures in China's medical institutions in 2024, reflecting an 8% year-on-year increase from 2023, indicating a growing market for postoperative pain management solutions [4] - In the first three quarters of 2025, Yiling Pharmaceutical achieved operating revenue of 5.868 billion yuan, with net profit exceeding 1 billion yuan, representing a year-on-year increase of 80.33%, and a 90.53% increase in net profit after excluding non-recurring gains and losses [4] - The company emphasizes that 2025 is a critical year for its "13th Five-Year Plan," focusing on long-term development amidst market complexities, enhancing management, expanding market reach, and implementing a comprehensive cost control system to improve profit margins [4]

Group 1 - The company held its 15th meeting of the 9th Board of Directors on January 22, 2026, via communication, with all 7 directors participating in the voting [2][4] - The Board approved the establishment of a "Compensation Management System for Directors and Senior Management" [3][5] - The Board also approved the revision of the "External Guarantee Management Measures" [7][8] - The Board approved the revision of the "Related Party Transaction Management Measures" [10][11] - The Board approved the revision of the "External Investment Management System" [13][14] - The Board approved the establishment of a "Management System for Resignation of Directors and Senior Management" [15][16] - The Board approved the revision of the "Internal Audit Management System" [17][18] Group 2 - The company announced a preliminary earnings forecast for 2025, expecting a net profit of approximately 106.33 million yuan, indicating a turnaround from a loss in the previous year [22][23] - The expected net profit after deducting non-recurring gains and losses is approximately 86.48 million yuan [24] - The previous year's net profit was a loss of 32.02 million yuan, with a loss of 20.59 million yuan after deducting non-recurring items [25] - The turnaround is attributed to strategic adjustments, including optimizing asset and personnel structure, and enhancing market expansion and cost control [26] - The company also benefited from a significant increase in net profit from its machine vision and information technology sectors [26] - Non-operating gains from financial assets also contributed positively, with an increase of 18.98 million yuan compared to the previous year [27] - Changes in accounting treatment due to the closure and transfer of underperforming subsidiaries also impacted the financial results [28]